SELECTED PUBLICATIONS

• Du et. al. Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy? Neuro-Oncology. 2024

• Wang et. al. B cell-based therapy produces antibodies that inhibit glioblastoma growth. Journal of Clinical Investigation. 2024

• Katz et. al. A covalent creatine kinase inhibitor ablates glioblastoma migration and sensitizes tumors to oxidative stress. Scientific Reports. 2024

• Kim et. al. Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro-Oncology. 2024

• Du et. al. Glioblastoma phagocytic cell death: balancing the opportunities for therapeutic manipulation. Cells. 2024

• Rashidi et. al. Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth. Cell Metabolism. 2024

• Chia et. al. The CXCL16-CXCR6 axis in glioblastoma modulates T-cell activity in a spatiotemporal context. Frontiers in Immunology. 2024

• Hou et. al. Antigen-presenting B cells promote TCF-1+ PD1-stem-like CD8+ T-cell proliferation in glioblastoma. Frontiers in Immunology. 2023

• Zhang et. al. GLUT3 regulates alternative macrophage signaling through a glucose transport–independent role. Journal of Clinical Investigation. 2023

• Fares et. al. Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases. Journal of Clinical Investigation. 2023

• Zhang et. al. STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nature Communications. 2023

• Dmello et. al. Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nature Communications. 2023

• Petrosyan et. al. Endoplasmic reticulum stress in the brain tumor immune microenvironment. Molecular Cancer Research. 2023

• Billingham et. al. Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation. Nature Immunology. 2022

• Ellingwood et. al. Therapeutic nanoparticles harness myeloid cells for brain tumor-targeted delivery and immunomodulation. Material Matters. 2022

• Sasaki et. al. Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma. J Neurosurg. 2022

• Larkin et. al. Myeloid cell classification and therapeutic opportunities within the glioblastoma tumor microenvironment in the single cell-omics era. Frontiers in Immunology. 2022

• Tripathi et. al. cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. F1000Research. 2022

• Miska et. al. Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma. Science Advances. 2021

• Cordero et. al. Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer. PNAS. 2021

• Lee-Chang et. al. Activation of 4-1BBL+ B cells with CD40 agonism and IFNgamma elicit potent immunity against glioblastoma. Journal of Experimental Medicine. 2020.

• Kanojia et. al. BET inhibition increases βIII-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine. Science Translational Medicine. 2020

• Bartolomé et. al. Protein tyrosine phosphatase-1B inhibition disrupts IL13Rα2-promoted invasion and metastasis in cancer cells. Cancers. 2020

• Rashidi et. al. GCN2 is essential for CD8+ T cell survival and function in murine models of malignant glioma. Cancer Immunology, Immunotherapy. 2020

• Zhang et. al. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. PNAS. 2019

• Lee-Chang et. al. Myeloid-derived suppressive cells promote B cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma. Cancer Immunology Research. 2019.

• Miska et. al. HIF-1α Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma. Cell Reports. 2019.

• Wu et. al. Repolarization of myeloid derived suppressor cells via magnetic nanoparticles to promote radiotherapy for glioma treatment. Nanomedicine: Nanotechnology, Biology and Medicine. 2019.

• Wu et. al. Race influences survival in glioblastoma patients with KPS ≥ 80 and associates with genetic markers of retinoic acid metabolism. Journal of Neuro-Oncology. 2019

• Panek et. al. Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model. Molecular neurobiology. 2018

• Kaverina et. al. Tamoxifen overrides autophagy inhibition in Beclin-1-deficient glioma cells and their resistance to adenovirus-mediated oncolysis via upregulation of PUMA and BAX. Oncogene. 2018

• Feng et. al. Self-Assembly of Gold Nanoparticles Shows Microenvironment-Mediated Dynamic Switching and Enhanced Brain Tumor Targeting. Theranostics. 2017

• Muroski et. al. Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate. Scientific Reports. 2017

• Zhang et. al. Dual-function nanocarriers with interfacial drug-interactive motifs for improved delivery of chemotherapeutic agents. Nanobiomaterials in Cancer Therapy: Applications of Nanobiomaterials. 2016

• Gao et. al. Functional surfactants: designing principles and applications in constructing nanomedicines. Nanomedicine: Nanotechnology Biology and Medicine. 2016

• Zhang et. al. Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy. Biomaterials. 2015

• Zhang et. al. Tunable pH-Responsive Polymeric Micelle for Cancer Treatment. ACS Macro Letters. 2015

• Zhang et. al. PEGylated Fmoc-amino acid conjugates as effective nanocarriers for improved drug delivery. Molecular Pharmaceutics. 2015

• Zhang et. al. Fmoc-conjugated PEG-vitamin E2 micelles for tumor-targeted delivery of paclitaxel: enhanced drug-carrier interaction and loading capacity. The AAPS Journal. 2014

• Zhang et. al. Targeted Delivery of Anticancer Agents via a Dual Function Nanocarrier with an Interfacial Drug-Interactive Motif. Biomacromolecules. 2014

• Zhang et. al. PEG-Farnesyl Thiosalicylic Acid Telodendrimer Micelles as An Improved Formulation for Targeted Delivery of Paclitaxel. Molecular Pharmaceutics. 2014

• Zhang et. al. A PEG-Fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials. 2014

• Zhang et. al.Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier. The AAPS Journal. 2014

• Zhang et. al. Characterization of Spherulites as a Lipidic Carrier for Low and High Molecular Weight Agents. Pharmaceutical Research. 2013

• Li et. al. RNAi in Liver Diseases in Advanced Delivery and Therapeutic Applications of RNAi. 2013

• Zhang et. al. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells. International Journal of Nanomedicine. 2012

• Ding et. al. PEG prodrug of gambogic acid: Amino acid and dipeptide spacer effects. Polymer. 2012

• Min et. al. Novel furoxan NO-donor pemetrexed derivatives: design, synthesis, and preliminary biological evaluation. Medicinal Chemistry Research. 2009

• Min et. al. Water‐soluble poly(ethylene glycol) prodrug of pemetrexed: Synthesis, characterization, and preliminary cytotoxicity. Journal of Applied Polymer Science. 2009

• Tang et. al. Water-soluble gambogic acid PEGylated prodrugs: synthesis, characterization, physicochemical properties and in vitro hydrolysis. Pharmazie. 2008.

• Zhang et. al. Water soluble poly(ethylene glycol) prodrug of silybin: Design, synthesis, and characterization. Journal of Applied Polymer Science. 2008